| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Hydrophobic pocket within the VP1 protein of human rhinoviruses (HRV) and enteroviruses. By binding to this pocket, WIN 54954 blocks viral uncoating, thereby preventing viral replication.
|
|---|---|
| ln Vitro |
For 50 out of 52 rhinovirus serotypes, WIN 54954 decreases plaque formation (MICs range from 0.007 to 2.2 μg/mL)[1]. WIN 54954 has an EC80 of 0.06 μg/mL and inhibits 15 frequently identified enteroviruses[1].
WIN 54954 reduces plaque formation of 50 out of 52 rhinovirus serotypes, with MICs ranging from 0.007 to 2.2 microg/mL. It inhibits 15 commonly isolated enteroviruses with an EC₈0 of 0.06 microg/mL. The compound demonstrates broad-spectrum activity against picornaviruses. |
| ln Vivo |
At doses of 2 and 100 mg/kg, respectively, WIN 54954 (2-100 mg/kg; po) prevents 50% of the mice from becoming paralyzed after contracting coxsackievirus A-9 and echovirus-9[1].
WIN 54954 (2-100 mg/kg; oral administration) protects 50% of mice from developing paralysis following infection with coxsackievirus 9 and echovirus-9 at doses of 2 and 100 mg/kg, respectively. This demonstrates its in vivo efficacy against enteroviral infections. |
| Enzyme Assay |
Viral capsid binding assays are performed using purified rhinovirus or enterovirus particles. The compound's ability to stabilize the viral capsid and inhibit uncoating is assessed. Radiolabeled or fluorescently labeled WIN 54954 can be used in binding studies to determine affinity for the VP1 hydrophobic pocket.
|
| Cell Assay |
Antiviral activity is assessed using plaque reduction assays. Cells (e.g., HeLa or MRC-5) are infected with various rhinovirus or enterovirus serotypes in the presence of serial dilutions of WIN 54954. After incubation, plaques are counted and IC₅0 or MIC values are calculated.
|
| Animal Protocol |
Coxsackievirus 9 or echovirus-9 infection models in mice: WIN 54954 is administered orally at doses ranging from 2 to 100 mg/kg. Animals are monitored for the development of paralysis, and the protective efficacy (e.g., 50% protection dose) is determined.
|
| ADME/Pharmacokinetics |
WIN 54954 is orally active and demonstrates favorable oral pharmacokinetics. It is a small molecule (MW 383.3) with good oral bioavailability. Detailed PK parameters (half-life, Cmax, AUC) have not been fully reported in the available literature.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data has been published for WIN 54954 in standard toxicology studies. As a research compound, it is not intended for human therapeutic use. In vivo studies in mice indicate that the compound is tolerated at doses up to 100 mg/kg.
|
| References | |
| Additional Infomation |
WIN54954 is an aromatic ether. WIN-54954 is a broad-spectrum antiviral drug against small RNA viruses.
WIN 54954 was developed from the lead compound Win 51711. It targets the VP1 capsid protein of picornaviruses, stabilizing the capsid and preventing viral uncoating. The compound has not received regulatory approval for clinical use and is primarily utilized in antiviral research. |
| Molecular Formula |
C18H20CL2N2O3
|
|---|---|
| Molecular Weight |
383.27
|
| Exact Mass |
382.085
|
| Elemental Analysis |
C, 56.41; H, 5.26; Cl, 18.50; N, 7.31; O, 12.52
|
| CAS # |
107355-45-3
|
| PubChem CID |
441048
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.294
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
25
|
| Complexity |
440
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=C(C2=NCCO2)C=C(Cl)C=1OCCCCCC1ON=C(C)C=1
|
| InChi Key |
JJDHAOLOHQTGMG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H20Cl2N2O3/c1-12-9-14(25-22-12)5-3-2-4-7-23-17-15(19)10-13(11-16(17)20)18-21-6-8-24-18/h9-11H,2-8H2,1H3
|
| Chemical Name |
Isoxazole, 5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-methyl-
|
| Synonyms |
WIN54954; WIN-54954; WIN 54954;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (260.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6091 mL | 13.0456 mL | 26.0913 mL | |
| 5 mM | 0.5218 mL | 2.6091 mL | 5.2183 mL | |
| 10 mM | 0.2609 mL | 1.3046 mL | 2.6091 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
